STAT+: At AACR, more strong results for Revolution Medicine’s KRAS drug, plus assurance from NCI’s director
At AACR, Revolution Medicines presented more eye-catching data about its KRAS-targeting treatment, and Anthony Letai declared the state of cancer research steady.
ORIGINAL SOURCE →via STAT News Health
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · conflict
- [CONFLICT] Intermodal Asia
- [CONFLICT] [Comment] Antibody-based malaria prevention in an intense perennial transmission setting
- [CONFLICT] [World Report] New Government aims to revitalise health in Hungary
- [CONFLICT] [Perspectives] Caring for the caregivers
- [CONFLICT] [Correspondence] Systematic health destruction in Iran by Operation Epic Fury
- [CONFLICT] [Correspondence] Microbiological governance and the Lancet Commission on Ukraine